IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

Core Viewpoint - IDEAYA Biosciences reported a quarterly loss of $1.49 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.67, marking an earnings surprise of -122.39% [1] Financial Performance - The company posted revenues of $7 million for the quarter ended December 2024, which aligns with the Zacks Consensus Estimate and represents an increase from $3.92 million in the same quarter last year [2] - Over the last four quarters, IDEAYA has only surpassed consensus EPS estimates once and has not beaten consensus revenue estimates during this period [2] Stock Performance - IDEAYA shares have declined approximately 14.6% since the beginning of the year, contrasting with the S&P 500's gain of 2.9% [3] - The company's near-term stock movements will largely depend on management's commentary during the earnings call [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.72 on revenues of $8.38 million, and for the current fiscal year, it is -$2.80 on revenues of $25.94 million [7] - The estimate revisions trend for IDEAYA is currently favorable, resulting in a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which IDEAYA belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]